Conference report - Phase III VISIBLE 2 study investigating subcutaneous vedolizumab for Crohn’s disease meets primary outcome for clinical remission
The results show that at week 52, significantly more patients on vedolizumab SC compared to placebo were in clinical remission (48.0% [n=132/275] vs. 34.3% [n=46/134] respectively; [p=0.008]), meeting the study’s primary endpoint.
Source:
PipelineReview.com
SPS commentary:
Vedolizumab is currently only licensed for intravenous administration.